Diatheva S.r.l.

Instituto Superiore Di Sanita

Istituto Superiore Di Sanita

Diego Moricoli

Valentina Fiori

Maurizio Cianfriglia

Michela Flego

Alessandro Ascione

Alessandra Mallano

Sabrina Domicini

Silvia Zamboni

Maria Cristina Balducci

Sabrina Dominici

Cosimo Damiano Carbonella

Maria Elena Laguardia

The present invention relates to a multivalent, preferably bivalent, antibody complex, more preferably a diabody, i.e. a bivalent scFv, capable of recognizing and binding the human protein CD99, a composition comprising said complex and the use thereof for diagnostic purposes and/or for the treatment and/or the follow-up of leukaemias and/or myelodysplastic syndromes. Furthermore, the present invention relates to antibodies, preferably monoclonal, of the immunoglobulins G group type capable of recognizing and binding the human protein CD99, a composition comprising said immunoglobulins and the medical use thereof, in particular for the treatment and/or the follow-up of cancer, preferably solid tumours that express CD99 and/or leukaemias and/or myelodysplastic syndromes.

Antibody complex and uses thereof

An anti-CEA scFv having an uncleaved Pel B leader sequence is surprisingly stable and is highly specific for CEA and CEACAM1.

Antibody derivatives

Growing community of inventors

Fano, Italy

Diego Moricoli